Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon, Inc. (IMNN)
Price$1.47Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | — | — | — | — | — | — | — |
| Research & development | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M | $14.7M | $15.0M | $9.4M | $15.8M | $19.9M | $14.7M |
| Operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M | $19.0M | $21.1M | $21.6M | $19.0M | $21.1M | $21.3M | $25.2M | $15.9M | $22.1M | $25.0M | $19.6M |
| Operating income | −$14.7M | −$19.1M | −$21.0M | −$24.9M | −$21.0M | −$18.5M | −$20.6M | −$21.1M | −$18.5M | −$20.6M | −$20.8M | −$24.7M | −$15.4M | −$22.1M | −$23.0M | −$19.6M |
| Operating margin | — | — | — | −4,984.31% | −4,201.44% | −3,697.28% | −4,113.09% | −4,213.01% | −3,693.69% | — | — | — | — | — | — | — |
| EBITDA | −$14.4M | −$18.9M | −$20.8M | −$24.2M | −$20.3M | −$17.7M | −$19.8M | −$20.7M | −$17.9M | −$19.6M | −$20.4M | −$24.3M | −$15.1M | −$21.9M | −$22.8M | −$19.5M |
| EBITDA margin | — | — | — | −4,837.99% | −4,060.85% | −3,548.98% | −3,968.76% | −4,141.64% | −3,583.08% | — | — | — | — | — | — | — |
| Net income | −$14.5M | −$18.6M | −$19.5M | −$35.9M | −$20.8M | −$21.5M | −$16.9M | −$11.9M | −$20.4M | −$22.1M | −$22.5M | −$25.5M | −$8.3M | −$26.6M | −$23.2M | −$18.8M |
| Net profit margin | — | — | — | −7,179.65% | −4,153.85% | −4,296.71% | −3,370.31% | −2,376.67% | −4,080.44% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$6.83 | -$16.94 | -$32.40 | -$75.45 | -$57.45 | -$151.20 | -$173.25 | -$153.00 | -$612.00 | -$2,675.25 | -$3,244.50 | -$4,347.00 | -$2,992.50 | -$10,836.00 | -$15,750.00 | -$1,064.00 |
| Diluted EPSper diluted share | -$6.83 | -$16.94 | -$32.40 | -$75.45 | -$57.45 | -$151.20 | -$173.25 | -$153.00 | -$612.00 | -$2,675.25 | -$3,244.50 | -$4,347.00 | -$2,992.50 | -$10,836.00 | -$15,750.00 | -$1,064.00 |
Owners
Reported shareholders
3.10%of listed shares
ARMISTICE CAPITAL, LLC144.77K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ARMISTICE CAPITAL, LLC | 3.10%144.77K shares |
Lindborg Stacy | ≈1.61%74.97K shares |
Tardugno Michael H | ≈1.38%64.61K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.01%46.97K shares |
Riverview Capital Advisers, LLC | 0.74%34.36K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.68%31.63K shares |
Faller Douglas Vincent | ≈0.47%21.9K shares |
Bragg Kimberly | ≈0.44%20.4K shares |
Virtu Financial LLC | 0.37%17.46K shares |
Dentzer James E | ≈0.32%14.96K shares |
Fritz Frederick J. | ≈0.30%14.1K shares |
VANGUARD FIDUCIARY TRUST CO | 0.28%13.27K shares |
NORTHERN TRUST CORP | 0.22%10.34K shares |
Braun Donald P | ≈0.20%9.32K shares |
Pellizzari Christine A | ≈0.17%8.14K shares |
UBS Group AG | 0.11%5.2K shares |
BlackRock, Inc. | 0.10%4.46K shares |
Tower Research Capital LLC (TRC) | 0.08%3.95K shares |
WELLS FARGO & COMPANY/MN | 0.07%3.34K shares |
Eylward Susan | ≈0.06%2.9K shares |
Percentages use 4.67M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 | Eylward SusanGeneral Counsel and Corp Sec | SellCommon Stock | 11.8K | $1.75 | $20.6K | 2.9K |
| Aug 20, 2024Form 4 | Braun Donald PDirector | BuyCommon Stock | 25.0K | $1.18 | $29.5K | 25.6K |
| Aug 15, 2024Form 4 | Lindborg StacyPresident and CEO | BuyImunon Common Stock | 25.0K | $0.98 | $24.5K | 264.2K |
| Aug 15, 2024Form 4 | Tardugno Michael HExecutive Chairman of Board | BuyImunon Common Stock | 25.0K | $1.03 | $25.8K | 353.3K |
Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...
